Description: Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. Its research phase products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia
Home Page: www.inhibikase.com
IKT Technical Analysis
3350 Riverwood Parkway SE
Atlanta,
GA
30339
United States
Phone:
678 392 3419
Officers
| Name | Title |
|---|---|
| Dr. Milton H. Werner Ph.D. | CEO, Pres & Director |
| Mr. Joseph Frattaroli CPA | Chief Financial Officer |
| Dr. Roger Rush | Head of Preclinical Research |
| Dr. Surendra Singh | Head of Chemistry, Manufacturing & Controls |
| Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D. | Medical Consultant, CEO of Clintrex Research Corp. & Science Advisor |
| Dan Williams | Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4918 |
| Price-to-Sales TTM: | 219.6323 |
| IPO Date: | 2020-12-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |